The study team developed an individual-level stochastic model to estimate economic returns from testing to detect antimicrobial resistance in gonorrhea. They reported per-episode cost-neutral prices for tests across a spectrum of resistance prevalences. When ceftriaxone resistance was absent, the per-test threshold approached zero dollars. As ceftriaxone resistance rose to 15% (proportion of infections resistant), the maximum per-test price that remained cost-neutral increased to as much as $48. For a scenario combining 50% ciprofloxacin resistance with 5% ceftriaxone resistance, the population-weighted per-test threshold was $7 (95% uncertainty interval [UI] $3–$11) for a ciprofloxacin-only assay and $13 (95% UI $8–$19) for a triple-target assay including a novel drug A. The authors presented these thresholds as direct economic measures to inform pricing and reimbursement decisions for resistance testing.
Investigators incorporated clinical and operational elements of gonorrhea care into the simulation. The model included infection prevalence, symptom status, diagnostic accuracy, resistance profiles, treatment pathways, and partner management. Costs were expressed in 2025 US dollars. The team evaluated three testing strategies: a single-target ciprofloxacin assay, a dual-target ciprofloxacin plus ceftriaxone assay, and a triple-target approach that also included a test for a novel agent referred to as drug A. The source did not provide additional methodological details about test turnaround times beyond assuming results could guide initial treatment at the same clinical visit, nor did it report specific parameter values for some inputs in the abstract.
Data indicated that per-episode direct medical cost savings depended strongly on background resistance levels. Low or absent ceftriaxone resistance yielded minimal per-test economic benefit against current empiric practice; the threshold price was near zero. With increasing ceftriaxone resistance, savings accrued because resistance-guided prescribing could avoid treatment failures and unnecessary use of last-line agents. At 15% ceftriaxone resistance the maximal per-test price that kept RGT cost-neutral reached $48. The authors calculated uncertainty intervals for key scenarios; for the scenario with 50% ciprofloxacin resistance and 5% ceftriaxone resistance, the ciprofloxacin-only test threshold was $7 (95% UI $3–$11) and the triple-target test threshold was $13 (95% UI $8–$19). Those estimates reflect the balance between test costs and expected reductions in direct medical spending per episode.
The modeling team extended economic valuation beyond per-episode savings to capture two broader components for men who have sex with men (MSM): costs attributable to the emergence of ceftriaxone resistance at a population level, and the avoided costs of developing new antibiotics. Including those system-level elements raised the estimated per-test value substantially. For a single-target assay, total per-test value among MSM ranged from $31 to $114; for a triple-target assay the range was $73 to $106. Those ranges depended on assumptions about whether clinicians would change prescribing behavior once ceftriaxone resistance reached 5%. The authors used these expanded valuations to quantify long-term and societal benefits that are not captured by per-episode accounting alone.
Investigators explored a wide array of resistance scenarios to capture plausible future trajectories of antibiotic susceptibility. They reported uncertainty intervals around key thresholds, reflecting parameter uncertainty in resistance prevalence and cost inputs. The abstract notes the use of broad scenario analyses but does not list every sensitivity tested; the source did not provide full parameter tables or all alternative scenario results within the abstract. The reported 95% UIs for the population-weighted thresholds illustrate the range of plausible per-test values when resistance and other inputs vary.
The authors identified several important limitations. First, the model assumed resistance results were available at the same clinical visit and could therefore guide initial treatment; the source did not report alternative assumptions about delayed results. Second, the model did not represent onward transmission dynamics or co-resistance between antibiotics, limiting the ability to capture transmission-mediated effects of resistance-guided treatment. Third, the study could estimate longer-term value only for MSM, rather than for the entire population over extended time horizons. Those constraints temper the interpretation of long-term or population-wide impacts.
The investigators concluded that resistance-guided therapy confers economic value across multiple dimensions — per-episode savings, reduced system-level costs from resistance emergence, and avoided antibiotic development expenditures — and that those values support investment in testing even when diagnostic prices are relatively high. The source explicitly framed the results to inform pricing and reimbursement decisions, and it emphasized that broader system-level benefits among MSM substantially increase the per-test economic case. The abstract does not report specific details about model calibration targets, sample sizes, or full parameter distributions; readers should consult the full article for complete methods and data tables.